Gene Alterations in Melanoma May Predict Immunotherapy Outcomes

​PHILADELPHIA — Among melanoma patients who were treated with immunotherapies, those whose tumors had mutations in the gene NRAS had better response and treatment outcomes than those whose tumors did not have NRAS mutations, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.